95 Result(s)

Article

Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference—a German expert perspective

To summarize the radiotherapy-relevant statements of the 18th St. Gallen Breast Cancer Consensus Conference and interpret the findings in light of German guideline recommendations.

PD Dr. med. David Krug, Maggie Banys-Paluchowski… in Strahlentherapie und Onkologie (2024)

Article

Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer

In DESTINY-Breast04 (DB-04), safety and efficacy of HER2-targeted antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) in previously treated HER2-low unresectable/metastatic breast cancer were establis...

Charo Garrido, Melissa Manoogian, Dhiraj Ghambire, Shawn Lucas… in Virchows Archiv (2024)

Article

Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study

In monarchE, adjuvant abemaciclib significantly improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), with sustained benefit beyond the 2-year treatment period. Abemaciclib d...

Matthew P. Goetz, Irfan Cicin, Laura Testa, Sara M. Tolaney… in npj Breast Cancer (2024)

Article

DNA methylation at quantitative trait loci (mQTLs) varies with cell type and nonheritable factors and may improve breast cancer risk assessment

To individualise breast cancer (BC) prevention, markers to follow a person’s changing environment and health extending beyond static genetic risk scores are required. Here, we analysed cervical and breast DNA ...

Chiara Herzog, Allison Jones, Iona Evans, Michal Zikan… in npj Precision Oncology (2023)

Article

PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant

Efficacy and quality of life (QoL) are key criteria for therapy selection in metastatic breast cancer (MBC). In hormone receptor positive (HR +) human epidermal growth factor receptor 2 negative (HER2 −) MBC, ...

Tom Degenhardt, Peter A. Fasching, Diana Lüftner, Volkmar Müller… in Trials (2023)

Article

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers

Mutations in the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K), encoded by the PIK3CA gene, cause dysregulation of the PI3K pathway in 35–40% of patients with HR+/HER2– breast cancer. Preclinica...

Katherine E. Hutchinson, Jessica W. Chen, Heidi M. Savage… in Genome Medicine (2023)

Article

PROCURE European consensus on breast cancer multigene signatures in early breast cancer management

Breast cancer multigene signatures (BCMS) have changed how patients with early-stage breast cancer (eBC) are managed, as they provide prognostic information and can be used to select patients who may avoid adj...

Giuseppe Curigliano, Fatima Cardoso, Michael Gnant, Nadia Harbeck… in npj Breast Cancer (2023)

Article

Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer

Patient-reported outcomes data assessing patients’ experience of immunotherapy treatment burden in potentially curable early-stage triple-negative breast cancer (TNBC) are lacking. These patient-reported data ...

Carlos H. Barrios, Shigehira Saji, Nadia Harbeck, Hong Zhang… in npj Breast Cancer (2022)

Article

Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial

Higher density of stromal tumor-infiltrating lymphocytes (sTILs) at baseline has been associated with increased rates of pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) in triple-neg...

Cornelia Kolberg-Liedtke, Friedrich Feuerhake, Madlen Garke… in Breast Cancer Research (2022)

Article

Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib

While cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, combined with endocrine therapy (ET), are becoming the standard-of-care for hormone receptor–positive/human epidermal growth factor...

Zhou Zhu, Nicholas C. Turner, Sherene Loi, Fabrice André… in npj Precision Oncology (2022)

Article

Author Correction: Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock

J. James E. Barrett, Chiara Herzog, Yoo-Na Kim, Thomas E. Bartlett… in Genome Biology (2022)

Article

The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C

Anthracycline/cyclophosphamide-taxane-containing chemotherapy (AC-T) is the standard of care in the adjuvant treatment of HER2-negative early breast cancer (EBC), but recent studies suggest omission of anthrac...

Amelie de Gregorio, Wolfgang Janni, Thomas W. P. Friedl… in British Journal of Cancer (2022)

Article

The role of E-Cadherin expression in primary site of breast cancer

The tumour’s ability to metastasize is the major cause for fatal outcomes in cancer diseases. In breast cancer, aberrant E-Cadherin expression has been linked to invasiveness and poor prognosis.

Nora Karsten, Thomas Kolben, Sven Mahner… in Archives of Gynecology and Obstetrics (2022)

Article

Gene signatures in patients with early breast cancer and relapse despite pathologic complete response

A substantial minority of early breast cancer (EBC) patients relapse despite their tumors achieving pathologic complete response (pCR) after neoadjuvant therapy. We compared gene expression (BC360; nCounter^® plat...

Simona Bruzas, Oleg Gluz, Nadia Harbeck, Peter Schmid, Javier Cortés… in npj Breast Cancer (2022)

Article

Increased risk for thromboembolic events from combination of a gynecologic malignancy with severe acute respiratory syndrome coronavirus 2 infection: a case report

During the severe acute respiratory syndrome coronavirus 2 pandemic, several patient groups are at particular risk. Mortality is higher among cancer patients and may be increased further by thromboembolic even...

Alexandra Stefan, Marija Petkovic, Alexander König… in Journal of Medical Case Reports (2022)

Article

Changes in gynecologic and breast cancer diagnoses during the first wave of the COVID-19 pandemic: analysis from a tertiary academic gyneco-oncological center in Germany

With the beginning of 2021, the world has been suffering from the COVID-19 pandemic for more than 1 year. More and more, we are able to evaluate side effects of the pandemic in the healthcare sector. A negativ...

Till Kaltofen, Friederike Hagemann, Nadia Harbeck… in Archives of Gynecology and Obstetrics (2022)

Article

Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock

A variety of epigenetic clocks utilizing DNA methylation changes have been developed; these clocks are either tissue-independent or designed to predict chronological age based on blood or saliva samples. Wheth...

James E. Barrett, Chiara Herzog, Yoo-Na Kim, Thomas E. Bartlett… in Genome Biology (2022)